Literature DB >> 17316562

Protection from lethal influenza virus challenge by oral type 1 interferon.

Manfred W Beilharz1, Joseph M Cummins, Alayne L Bennett.   

Abstract

The persistence of highly pathogenic avian influenza within wild bird populations has forged interest in control measures to limit a possible human pandemic. We therefore investigated the efficacy of low dose oral administration of IFN-alpha as a potential therapy against influenza infection in a murine model. We have identified an optimal low oral dose of IFN-alpha that when delivered daily as prophylactic therapy protects C57BL/6J mice from a lethal challenge with mouse adapted human influenza virus A/PR/8/34 (H1N1). These results provide strong support for the application of low dose type 1 IFN pretreatment to human influenza control.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17316562     DOI： 10.1016/j.bbrc.2007.02.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  35 in total

1.  The microbial metabolite desaminotyrosine protects from influenza through type I interferon.

Authors:  Ashley L Steed; George P Christophi; Gerard E Kaiko; Lulu Sun; Victoria M Goodwin; Umang Jain; Ekaterina Esaulova; Maxim N Artyomov; David J Morales; Michael J Holtzman; Adrianus C M Boon; Deborah J Lenschow; Thaddeus S Stappenbeck
Journal:  Science       Date:  2017-08-04       Impact factor: 47.728

Review 2.  Innate immune evasion strategies of influenza viruses.

Authors:  Benjamin G Hale; Randy A Albrecht; Adolfo García-Sastre
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

3.  An alternative model for type I interferon induction downstream of human TLR2.

Authors:  Timo Oosenbrug; Michel J van de Graaff; Mariëlle C Haks; Sander van Kasteren; Maaike E Ressing
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

4.  Pharmacologic activation of the innate immune system to prevent respiratory viral infections.

Authors:  Guanjun Cheng; Liang-Chuan S Wang; Zvi G Fridlender; Guang-Shing Cheng; Bei Chen; Nilam S Mangalmurti; Vassiliki Saloura; Zaifang Yu; Veena Kapoor; Krystyna Mozdzanowska; Edmund Moon; Jing Sun; James L Kreindler; Noam A Cohen; Andrew J Caton; Jan Erikson; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-12-10       Impact factor: 6.914

5.  Interferon Inducer IFI35 regulates RIG-I-mediated innate antiviral response through mutual antagonism with Influenza protein NS1.

Authors:  Hui Yang; Wendy Winkler; Xiaopeng Wu
Journal:  J Virol       Date:  2021-03-10       Impact factor: 5.103

6.  Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Authors:  Neal Van Hoeven; Jessica A Belser; Kristy J Szretter; Hui Zeng; Peter Staeheli; David E Swayne; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

7.  Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand.

Authors:  Christina C N Wu; Brian Crain; Shiyin Yao; Mojgan Sabet; Fitzgerald S Lao; Rommel I Tawatao; Michael Chan; Donald F Smee; Justin G Julander; Howard B Cottam; Donald G Guiney; Maripat Corr; Dennis A Carson; Tomoko Hayashi
Journal:  J Innate Immun       Date:  2013-11-01       Impact factor: 7.349

8.  Oral delivery of oligomeric procyanidins in Apple Poly® enhances type I IFN responses in vivo.

Authors:  Deann T Snyder; Amanda Robison; Sharon Kemoli; Emily Kimmel; Jeff Holderness; Mark A Jutila; Jodi F Hedges
Journal:  J Leukoc Biol       Date:  2014-01-13       Impact factor: 4.962

9.  Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment.

Authors:  John Steel; Peter Staeheli; Samira Mubareka; Adolfo García-Sastre; Peter Palese; Anice C Lowen
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

10.  Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.

Authors:  Brice E Barefoot; Kathleen Athearn; Christopher J Sample; Elizabeth A Ramsburg
Journal:  Vaccine       Date:  2009-10-09       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.